Loading...
•
Jun 30, 2022
Cabaletta Bio Q2 2022 Earnings Report
Reported financial results for the second quarter and provided a business update.
Key Takeaways
Cabaletta Bio reported its second quarter financial results, highlighting the advancement of the DesCAARTes™ trial and the anticipation of upcoming milestones. With sufficient cash to fund operations through Q1 2024, the company focuses on developing targeted cell therapies for autoimmune diseases.
DesCAARTes™ trial is advancing through additional cohorts, including higher doses and a planned combination cohort.
Cabaletta plans to present 6-month clinical and translational data from cohort A4 and 28-day safety data from cohort A5 at the upcoming European Association of Dermatology and Venereology Congress.
Health Canada accepted the Clinical Trial Application for the MusCAARTes™ trial, allowing for patient enrollment in Canada.
Cabaletta had cash on hand to fund operations through the first quarter of 2024.
Forward Guidance
Cabaletta anticipates continued progress with its clinical trials and is financially positioned to fund operations through Q1 2024.
Positive Outlook
- Advancing the DesCAARTes™ trial through additional cohorts.
- Presenting clinical data at the European Association of Dermatology and Venereology Congress.
- Health Canada accepted the Clinical Trial Application for the MusCAARTes™ trial.
- Initiating a first-in-human trial for MuSK-CAART in 2022.
- Participating in upcoming investor conferences
Challenges Ahead
- Risk that signs of biologic activity or persistence may not inform long-term results
- Risks related to clinical trial site activation or enrollment rates that are lower than expected
- Risks related to unexpected safety or efficacy data observed during clinical studies
- The risk that any one or more of Cabaletta’s product candidates will not be successfully developed and commercialized
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...